BioCentury
ARTICLE | Top Story

Bristol-Myers, Kai in cardiovascular deal

May 13, 2008 11:52 PM UTC

Bristol-Myers (NYSE:BMY) received exclusive, worldwide rights to develop and commercialize KAI-9803 from Kai (South San Francisco, Calif.). The protein kinase C (PKC) delta inhibitor, which has Fast T...